Is Neurosense Therapeutics Stock a Good Investment?
Neurosense Therapeutics Investment Advice | NRSN |
Recommendations are not available for this entity. Please try other suggestions below
We are unable to locate Neurosense Therapeutics Advice at this time.
If you believe the indicator you are trying to look up is valid, please let us know, and we will check it out. Check all delisted instruments across multiple markets.| Symbol | NRSN |
| Name | Neurosense Therapeutics |
| Type | Stock |
| Country | United States |
| Exchange | NASDAQ |
Other Suggestions
| NR | NR Old | CompanyDelisted |
| NREF-PA | NexPoint Real Estate | Company |
| NRC | National Research Corp | Company |
| NRK | Nuveen New York | Fund |
| NRES | Xtrackers RREEF Global | ETF |
| NRU | SP Global Natural | Index |
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Examine Neurosense Therapeutics Stock
Researching Neurosense Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.36. Neurosense Therapeutics had not issued any dividends in recent years.
To determine if Neurosense Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurosense Therapeutics' research are outlined below:
| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Neurosense Therapeutics may become a speculative penny stock | |
| Neurosense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 30.0% of the company outstanding shares are owned by corporate insiders |
Neurosense Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurosense Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurosense Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Neurosense Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.55 M.Basic technical analysis of Neurosense Stock
As of the 23rd of September, Neurosense Therapeutics secures the Risk Adjusted Performance of (0.04), standard deviation of 7.51, and Mean Deviation of 4.53. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurosense Therapeutics, as well as the relationship between them.Neurosense Therapeutics' Outstanding Corporate Bonds
Neurosense Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurosense Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurosense bonds can be classified according to their maturity, which is the date when Neurosense Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Neurosense Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurosense Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 4.53 | |||
| Coefficient Of Variation | (1,343) | |||
| Standard Deviation | 7.51 | |||
| Variance | 56.34 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (2.12) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 49.42 | |||
| Value At Risk | (8.87) | |||
| Potential Upside | 9.52 | |||
| Skewness | (2.06) | |||
| Kurtosis | 12.02 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 4.53 | |||
| Coefficient Of Variation | (1,343) | |||
| Standard Deviation | 7.51 | |||
| Variance | 56.34 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (2.12) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 49.42 | |||
| Value At Risk | (8.87) | |||
| Potential Upside | 9.52 | |||
| Skewness | (2.06) | |||
| Kurtosis | 12.02 |
Consider Neurosense Therapeutics' intraday indicators
Neurosense Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurosense Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 10803.44 | |||
| Daily Balance Of Power | (0.17) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1.26 | |||
| Day Typical Price | 1.26 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 29.95 |
Neurosense Stock media impact
There is far too much social signal, news, headlines, and media speculation about Neurosense Therapeutics that are available to investors today. This information is accessible both publicly - through Neurosense Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Neurosense-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Neurosense Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurosense Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurosense Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurosense Therapeutics alpha.
Neurosense Therapeutics Corporate Management
| Sharon Vered | Global CMC | Profile | |
| Diana Shtossel | Head Affairs | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Nedira SalzmanFrenkel | Global Devel | Profile | |
| Yael Barak | Head Compliance | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neurosense Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.